Jun Gong, Medical oncologist and researcher in gastrointestinal and genitourinary cancers at Cedars-Sinai, shared a post on X:
“Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors (35/40 #mCRC pts) enrolled to IV or IP administration depending on predominant peritoneal Mets. IP ORR 25% vs 8% IV, 100% G3-4 heme toxicity, G1-2 CRS 62.5% all patients.”
Source: Jun Gong/X
